Treatment strategies for the prevention of heart failure

被引:5
作者
Grodin J.L. [1 ]
Tang W.H.W. [1 ]
机构
[1] Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, 9500 Euclid Avenue
基金
美国国家卫生研究院;
关键词
Angiotensin converting enzyme inhibitor; Angiotensin receptor blocker; Beta-blocker; Biomarkers; Brain natriuretic peptide; Cardiomyopathy; Coronary artery disease; Diabetes mellitus; Heart failure; Hyperlipidemia; Hypertension; Insulin resistance; Left bundle branch block; Left ventricular hypertrophy; Obesity; Prevention; Statins; Thiazide diuretic; Troponin;
D O I
10.1007/s11897-013-0154-8
中图分类号
学科分类号
摘要
With the astounding morbidity and mortality associated with heart failure (HF), preventive approaches have been explored. Controlling hypertension to prevent HF is well-established, especially with sodium restriction and thiazide-based antihypertensive therapies showing potential advantages. Control of dyslipidemia with aggressive statin therapy is particularly beneficial in preventing HF in the setting of acute coronary syndrome. The HOPE study also established the benefit of ACE inhibitors in the prevention of HF in high-risk subjects. Meanwhile old data supporting tight glycemic control in preventing HF have not been confirmed, suggesting the complexity of diabetic cardiomyopathy. Avoiding tobacco use and other known cardiotoxins are likely helpful. While there has been substantial development in identifying biomarkers predicting future development of HF, therapeutic interdiction guided by biomarker levels have yet to be established, even though it offers hope in modulating the natural history of the development of HF in at-risk individuals. © 2013 Springer Science+Business Media New York.
引用
收藏
页码:331 / 340
页数:9
相关论文
共 108 条
[1]  
Heidenreich P.A., Trogdon J.G., Khavjou O.A., Et al., Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association, Circulation, 123, 8, pp. 933-944, (2011)
[2]  
Roger V.L., Weston S.A., Redfield M.M., Et al., Trends in heart failure incidence and survival in a community-based population, JAMA, 292, 3, pp. 344-350, (2004)
[3]  
Yancy C.W., Jessup M., Bozkurt B., Et al., ACCF/AHA Guideline for the management of heart failure: Executive summary: A report of the american college of cardiology foundation/American heart association task force on practice guidelines, J Am Coll Cardiol, (2013)
[4]  
Drazner M.H., The progression of hypertensive heart disease, Circulation, 123, 3, pp. 327-334, (2011)
[5]  
Chobanian A.V., Bakris G.L., Black H.R., Et al., Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure, Hypertension, 42, 6, pp. 1206-1252, (2003)
[6]  
Levitan E.B., Wolk A., Mittleman M.A., Consistency with the DASH diet and incidence of heart failure, Arch Intern Med, 169, 9, pp. 851-857, (2009)
[7]  
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA, 288, 23, pp. 2981-2997, (2002)
[8]  
Beckett N.S., Peters R., Fletcher A.E., Et al., Treatment of hypertension in patients 80 years of age or older, N Engl J Med, 358, 18, pp. 1887-1898, (2008)
[9]  
Sciarretta S., Palano F., Tocci G., Baldini R., Volpe M., Antihypertensive treatment and development of heart failure in hypertension: A Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk, Arch Intern Med, 171, 5, pp. 384-394, (2011)
[10]  
Bangalore S., Wild D., Parkar S., Kukin M., Messerli F.H., Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis, J Am Coll Cardiol, 52, 13, pp. 1062-1072, (2008)